Expression of P-glycoprotein in HeLa cells confers resistance to ceramide cytotoxicity

International Journal of Oncology

Volumn 37, Issue 6, 2010, Pages 1591-1597

  Chapman, Jacqueline V ^a   Gouazé Andersson, Valérie ^a   Cabot, Myles C ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

Author keywords

Ceramide; Glucosylceramide; HeLa cells; P glycoprotein

Indexed keywords

CERAMIDE; CERAMIDE GLUCOSYLTRANSFERASE; GLUCOSYLCERAMIDE; GLYCOPROTEIN P; SPHINGOMYELIN; TAMOXIFEN;

ARTICLE; CYTOTOXICITY; GENE EXPRESSION; GLYCOSYLATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; UTERINE CERVIX CANCER;

EID: 78649955814     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo_00000813     Document Type: Article

References (50)

1. Lutzker SG and Levine AJ: Apoptosis and cancer chemotherapy. Cancer Treat Res 87: 345-356, 1996.
2. Gewirtz DA, Holt SE and Grant S (eds): Apoptosis, Senescence, and Cancer. 2nd edition. Humana Press Inc., Totowa, NJ, 2007.
3. Jaffrezou JP, Laurent G and Levade T: Ceramide in regulation of apoptosis. Implication in multitoxicant resistance. Subcell Biochem 36: 269-284, 2002.
4. Zheng W, Kollmeyer J, Symolon H, et al: Ceramides and other bioactive sphingolipid backbones in health and disease: lipidomic analysis, metabolism and roles in membrane structure, dynamics, signaling and autophagy. Biochim Biophys Acta 1758: 1864-1884, 2006.
5. Saddoughi SA, Song P and Ogretmen B: Roles of bioactive sphingolipids in cancer biology and therapeutics. Subcell Biochem 49: 413-440, 2008.
6. Jarvis WD and Grant S: The role of ceramide in the cellular response to cytotoxic agents. Curr Opin Oncol 10: 552-559, 1998.
7. Gouaze-Andersson V and Cabot MC: Glycosphingolipids and drug resistance. Biochim Biophys Acta 1758: 2096-2103, 2006.
8. Lucci A, Han TY, Liu YY, Giuliano AE and Cabot MC: Modification of ceramide metabolism increases cancer cell sensitivity to cytotoxics. Int J Oncol 15: 541-546, 1999.
9. Liu YY, Han TY, Giuliano AE and Cabot MC: Ceramide glycosylation potentiates cellular multidrug resistance. FASEB J 15: 719-730, 2001.
10. Deng W, Li R, Guerrera M, Liu Y and Ladisch S: Transfection of glucosylceramide synthase antisense inhibits mouse melanoma formation. Glycobiology 12: 145-152, 2002.
11. Sietsma H, Veldman RJ, Kolk D, et al: 1-phenyl-2-decanoylamino-3- morpholino-1-propanol chemosensitizes neuroblastoma cells for taxol and vincristine. Clin Cancer Res 6: 942-948, 2000.
12. Olshefski RS and Ladisch S: Glucosylceramide synthase inhibition enhances vincristine-induced cytotoxicity. Int J Cancer 93: 131-138, 2001.
13. Bleicher RJ and Cabot MC: Glucosylceramide synthase and apoptosis. Biochim Biophys Acta 1585: 172-178, 2002.
14. Lavie Y, Cao H, Bursten SL, Giuliano AE and Cabot MC: Accumulation of glucosylceramides in multidrug-resistant cancer cells. J Biol Chem 271: 19530-19536, 1996.
15. Lucci A, Cho WI, Han TY, Giuliano AE, Morton DL and Cabot MC: Glucosylceramide: a marker for multiple-drug resistant cancers. Anticancer Res 18: 475-480, 1998. (Pubitemid 28174859)
16. Bose R, Verheij M, Haimovitz-Friedman A, Scotto K, Fuks Z and Kolesnick R: Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals. Cell 82: 405-414, 1995.
17. Jaffrezou JP, Levade T, Bettaieb A, et al: Daunorubicin-induced apoptosis: triggering of ceramide generation through sphingomyelin hydrolysis. EMBO J 15: 2417-2424, 1996. (Pubitemid 26151181)
18. Maurer BJ, Metelitsa LS, Seeger RC, Cabot MC and Reynolds CP: Increase of ceramide and induction of mixed apoptosis/ necrosis by N-(4-hydroxyphenyl)- retinamide in neuroblastoma cell lines. J Natl Cancer Inst 91: 1138-1146, 1999.
19. Lavie Y, Cao H, Volner A, et al: Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells. J Biol Chem 272: 1682-1687, 1997.
20. De Rosa MF, Sillence D, Ackerley C and Lingwood C: Role of multiple drug resistance protein 1 in neutral but not acidic glycosphingolipid biosynthesis. J Biol Chem 279: 7867-7876, 2004.
21. Shabbits JA and Mayer LD: P-glycoprotein modulates ceramide-mediated sensitivity of human breast cancer cells to tubulin-binding anticancer drugs. Mol Cancer Ther 1: 205-213, 2002.
22. Eckford PD and Sharom FJ: The reconstituted P-glycoprotein multidrug transporter is a flippase for glucosylceramide and other simple glycosphingolipids. Biochem J 389: 517-526, 2005.
23. van Helvoort A, Smith AJ, Sprong H, et al: MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell 87: 507-517, 1996. (Pubitemid 26374324)
24. Borst P, Zelcer N and van Helvoort A: ABC transporters in lipid transport. Biochim Biophys Acta 1486: 128-144, 2000.
25. Aleman C, Annereau JP, Liang XJ, et al: P-glycoprotein, expressed in multidrug resistant cells, is not responsible for alterations in membrane fluidity or membrane potential. Cancer Res 63: 3084-3091, 2003. (Pubitemid 36735857)
26. Callaghan R and Higgins CF: Interaction of tamoxifen with the multidrug resistance P-glycoprotein. Br J Cancer 71: 294-299, 1995.
27. Shao YM, Ayesh S and Stein WD: Mutually co-operative interactions between modulators of P-glycoprotein. Biochim Biophys Acta 1360: 30-38, 1997. (Pubitemid 27083657)
28. Bekaii-Saab TS, Perloff MD, Weemhoff JL, Greenblatt DJ and von Moltke LL: Interactions of tamoxifen, N-desmethyltamoxifen and 4-hydroxytamoxifen with P-glycoprotein and CYP3A. Biopharm Drug Dispos 25: 283-289, 2004.
29. Bielawska A and Hannun YA: Preparation of radiolabeled ceramides and phosphosphingolipids. Methods Enzymol 311: 499-518, 2000.
30. Lee L, Abe A and Shayman JA: Improved inhibitors of glucosylceramide synthase. J Biol Chem 274: 14662-14669, 1999.
31. Shen DW, Cardarelli C, Hwang J, et al: Multiple drug-resistant human KB carcinoma cells independently selected for high-level resistance to colchicine, adriamycin, or vinblastine show changes in expression of specific proteins. J Biol Chem 261: 7762-7770, 1986. (Pubitemid 17208699)
32. Gouaze V, Liu YY, Prickett CS, Yu JY, Giuliano AE and Cabot MC: Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs. Cancer Res 65: 3861-3867, 2005. (Pubitemid 40616367)
33. Gouaze V, Yu JY, Bleicher RJ, et al: Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy. Mol Cancer Ther 3: 633-639, 2004. (Pubitemid 39193742)
34. Shukla GS and Radin NS: Glucosyceramide synthase of mouse kidney: further characterization with an improved assay method. Arch Biochem Biophys 283: 372-378, 1990.
35. Gouaze-Andersson V, Yu JY, Kreitenberg AJ, Bielawska A, Giuliano AE and Cabot MC: Ceramide and glucosylceramide upregulate expression of the multidrug resistance gene MDR1 in cancer cells. Biochim Biophys Acta 1771: 1407-1417, 2007.
36. Ohnishi A, Matsuo H, Yamada S, et al: Effect of furanocoumarin derivatives in grapefruit juice on the uptake of vinblastine by Caco-2 cells and on the activity of cytochrome P450 3A4. Br J Pharmacol 130: 1369-1377, 2000.
37. Wang H, Charles AG, Frankel AJ and Cabot MC: Increasing intracellular ceramide: an approach that enhances the cytotoxic response in prostate cancer cells. Urology 61: 1047-1052, 2003.
38. Cabot MC, Giuliano AE, Volner A and Han TY: Tamoxifen retards glycosphingolipid metabolism in human cancer cells. FEBS Lett 394: 129-131, 1996.
39. Nathan FE, Berd D, Sato T and Mastrangelo MJ: Paclitaxel and tamoxifen: An active regimen for patients with metastatic melanoma. Cancer 88: 79-87, 2000. (Pubitemid 30027682)
40. Rao US, Fine RL and Scarborough GA: Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol 48: 287-292, 1994. (Pubitemid 24243970)
41. Tran MA, Smith CD, Kester M and Robertson GP: Combining nanoliposome ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development. Clin Cancer Res 14: 3571-3581, 2008.
42. Stover TC, Kim YS, Lowe TL and Kester M: Thermoresponsive and biodegradable linear-dendritic nanoparticles for targeted and sustained release of a pro-apoptotic drug. Biomaterials 29: 359-369, 2008.
43. Veldman RJ, Klappe K, Hinrichs J, et al: Altered sphingolipid metabolism in multidrug-resistant ovarian cancer cells is due to uncoupling of glycolipid biosynthesis in the Golgi apparatus. FASEB J 16: 1111-1113, 2002.
44. Dijkhuis AJ, Douwes J, Kamps W, Sietsma H and Kok JW: Differential expression of sphingolipids in P-glycoprotein or multidrug resistance-related protein 1 expressing human neuroblastoma cell lines. FEBS Lett 548: 28-32, 2003. (Pubitemid 37281245)
45. Molinari A, Cianfriglia M, Meschini S, Calcabrini A and Arancia G: P-glycoprotein expression in the Golgi apparatus of multidrug-resistant cells. Int J Cancer 59: 789-795, 1994.
46. Molinari A, Calcabrini A, Meschini S, et al: Subcellular detection and localization of the drug transporter P-glycoprotein in cultured tumor cells. Curr Protein Pept Sci 3: 653-670, 2002. (Pubitemid 35331550)
47. Halter D, Neumann S, van Dijk SM, et al: Pre- and post-Golgi translocation of glucosylceramide in glycosphingolipid synthesis. J Cell Biol 179: 101-115, 2007.
48. Turzanski J, Grundy M, Shang S, Russell N and Pallis M: P-glycoprotein is implicated in the inhibition of ceramide-induced apoptosis in TF-1 acute myeloid leukemia cells by modulation of the glucosylceramide synthase pathway. Exp Hematol 33: 62-72, 2005.
49. Liu YY, Han TY, Giuliano AE and Cabot MC: Expression of glucosylceramide synthase, converting ceramide to glucosylceramide, confers adriamycin resistance in human breast cancer cells. J Biol Chem 274: 1140-1146, 1999. (Pubitemid 29058091)
50. Klappe K, Hinrichs JW, Kroesen BJ, Sietsma H and Kok JW: MRP1 and glucosylceramide are coordinately over expressed and enriched in rafts during multidrug resistance acquisition in colon cancer cells. Int J Cancer 110: 511-522, 2004. (Pubitemid 38658016)